| MeSH term | MeSH ID | Detail |
|---|---|---|
| Inflammatory Bowel Diseases | D015212 | 9 associated lipids |
| Reperfusion Injury | D015427 | 65 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Fatty Liver | D005234 | 48 associated lipids |
| Cataract | D002386 | 34 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Metalidis C et al. | Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. | 2011 | Transplantation | pmid:21544031 |
| Dumont FJ et al. | A tacrolimus-related immunosuppressant with reduced toxicity. | 1998 | Transplantation | pmid:9448138 |
| Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
| Roth D et al. | A prospective study of hepatitis C virus infection in renal allograft recipients. | 1996 | Transplantation | pmid:8623154 |
| Shin BH et al. | Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. | 2014 | Transplantation | pmid:24342979 |
| Yoon SH et al. | CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). | 2013 | Transplantation | pmid:23364483 |
| Calmus Y et al. | Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. | 2010 | Transplantation | pmid:20495510 |
| Zoppo A et al. | Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. | 1999 | Transplantation | pmid:10551656 |
| Egli A et al. | Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. | 2009 | Transplantation | pmid:19935369 |
| Takahara S et al. | The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. | 1992 | Transplantation | pmid:1373537 |
| Johnson MC et al. | QT prolongation and Torsades de Pointes after administration of FK506. | 1992 | Transplantation | pmid:1373538 |
| Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
| Weir MR et al. | Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. | 2017 | Transplantation | pmid:26950714 |
| Timmermann W et al. | Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. | 1999 | Transplantation | pmid:10401762 |
| Fujimura Y and Owen RL | Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. | 2002 | Transplantation | pmid:11965030 |
| Castells L et al. | Liver transplantation in HIV-HCV coinfected patients: a case-control study. | 2007 | Transplantation | pmid:17297413 |
| Khanna A et al. | Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. | 1999 | Transplantation | pmid:10071036 |
| Bozorgzadeh A et al. | Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. | 2004 | Transplantation | pmid:15087773 |
| Benigni A et al. | The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. | 1992 | Transplantation | pmid:1279848 |
| Diem HV et al. | Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. | 2003 | Transplantation | pmid:12777858 |
| Butani L et al. | Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. | 2003 | Transplantation | pmid:12883183 |
| Smets F et al. | Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. | 2002 | Transplantation | pmid:12042647 |
| David-Neto E et al. | Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. | 2017 | Transplantation | pmid:27482958 |
| Sood P et al. | Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. | 2012 | Transplantation | pmid:23018881 |
| Couzi L et al. | Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. | 2008 | Transplantation | pmid:18946343 |
| Horner BM et al. | Recipient damage after musculocutaneous transplant rejection. | 2008 | Transplantation | pmid:18946349 |
| Andoh TF et al. | Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. | 1994 | Transplantation | pmid:7509514 |
| Higgins RM et al. | Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. | 2004 | Transplantation | pmid:14966430 |
| Woodle ES et al. | A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. | 1996 | Transplantation | pmid:8830821 |
| Herlenius G et al. | Chronic kidney disease--a common and serious complication after intestinal transplantation. | 2008 | Transplantation | pmid:18622286 |
| Ceulemans LJ et al. | Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. | 2015 | Transplantation | pmid:25695790 |
| Mañez R et al. | Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. | 1995 | Transplantation | pmid:7537400 |
| Pacifico L et al. | Tacrolimus and food allergy. | 2003 | Transplantation | pmid:14688538 |
| Mourad M et al. | Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. | 2005 | Transplantation | pmid:16249748 |
| Vyas S et al. | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. | 1999 | Transplantation | pmid:10030303 |
| Ji E et al. | Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. | 2012 | Transplantation | pmid:22992768 |
| Hanto DW and Chudzinski R | What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? | 2009 | Transplantation | pmid:19155968 |
| Muthukkumar S et al. | Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. | 1995 | Transplantation | pmid:7544036 |
| Muraki T et al. | Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. | 1995 | Transplantation | pmid:7544038 |
| Boots JM et al. | Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. | 2002 | Transplantation | pmid:12499885 |
| Hebert MF et al. | Interpreting tacrolimus concentrations during pregnancy and postpartum. | 2013 | Transplantation | pmid:23274970 |
| Molmenti EP et al. | Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. | 2001 | Transplantation | pmid:11213072 |
| Thai NL et al. | Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. | 2006 | Transplantation | pmid:17198247 |
| Min SI et al. | CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. | 2010 | Transplantation | pmid:21076384 |
| Jain AB et al. | Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. | 1995 | Transplantation | pmid:7545836 |
| Vincenti F et al. | One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8669100 |
| Letavernier E et al. | Proteinuria following a switch from calcineurin inhibitors to sirolimus. | 2005 | Transplantation | pmid:16314786 |
| Wai LE et al. | Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. | 2008 | Transplantation | pmid:18192925 |
| Burger CI et al. | Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. | 2010 | Transplantation | pmid:20440199 |
| Wang HD et al. | Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. | 2018 | Transplantation | pmid:29298238 |